MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 553-559, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-772402
ABSTRACT
Recently, targeted therapy has achieved great success in the treatment of non-small cell lung cancer (NSCLC) patients. Mesenchymal to epithelial transition factor (MET) is considered to be another important molecular target for NSCLC since epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Accumulating clinical trials and case reports have confirmed that MET inhibitors exhibited a potential prospect in treating patients with MET 14 exon skipping alterations, suggesting that MET 14 exon skipping mutation might be an effective biomarker for MET inhibitors, which remains to be confirmed by more clinical data. This review summarizes current research about the molecular mechanism, clinicopathological characterization, treatment strategies and drug resistance mechanisms of MET 14 exon skipping alterations in NSCLC.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Exons
/
Carcinoma, Non-Small-Cell Lung
/
Proto-Oncogene Proteins c-met
/
Drug Therapy
/
Molecular Targeted Therapy
/
Genetics
/
Lung Neoplasms
/
Mutation
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS